Skip to content

Concerns about efficacy, cost and side-effects possible barriers to PrEP uptake in groups with high HIV risk

HIV damages B-cells as well as T-cells: new treatment targets identified

Large gaps in the HIV prevention evidence base

Tropism impacts on virological success of first-line HIV therapy

HIV tests every 3 to 6 months suggested for all sexually active gay men in US

Switch from efavirenz to raltegravir improves mood and lipid profiles

UNAIDS: Treat 15 million by 2015

HIV-positive patients who receive therapy for acute HCV can be cured with just 24 weeks of therapy

Thirty years on

Thirty years on